Zidesamtinib, known commercially as Jideytro, functions as a selective inhibitor designed for patients who have already undergone targeted therapy. The drug’s path to market follows GSK’s recent acquisition of Nuvalent, a transaction that bolstered the company’s specialized oncology portfolio earlier this year. By securing this approval, the company gains a foothold in a competitive therapeutic area where precision medicine continues to redefine standard care protocols for advanced lung disease.
In section Market Quotes
GSK Secures First U.S. Lung Cancer Drug Approval with Jideytro
The U.S. Food and Drug Administration has cleared Jideytro for use in specific adult patients with non-small cell lung cancer, marking a strategic milestone for GSK. This regulatory nod represents the British pharmaceutical giant’s debut entry into the oncology space specifically targeting lung malignancy after previous systemic treatments failed.
Comments (0)
No comments yet. Be the first!